RESEARCH PAPER
Dyslipidemia among HIV-positive children receiving antiretroviral therapy in Indonesia
1
Department of Child Health, Universitas Indonesia – Cipto Mangunkusumo General Hospital, Indonesia
Submission date: 2020-04-27
Final revision date: 2020-09-02
Acceptance date: 2020-09-07
Publication date: 2021-04-12
HIV & AIDS Review 2021;20(1):46-51
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Antiretroviral (ARV) therapy has changed the status of human immunodeficiency virus (HIV) infection from a high-mortality disease into a chronic one. One of the consequences of long-term use of ARV medications is dyslipidemia, which may progress to cardiovascular disease in the future. The aim of the study was to measure the rate of dyslipidemia among HIV-infected children receiving ARV therapy and related risk factors.
Material and methods:
A cross-sectional study was conducted at pediatric outpatient clinic, Cipto Mangunkusumo Hospital, Jakarta, Indonesia, from January to July 2019. Lipid profile was examined on 96 eligible subjects and data regarding nutritional status, clinical stage at diagnosis, latest immunosuppression status, latest viral load (VL) value, and latest ARV combination used were obtained from medical records. Bivariate and multivariate analysis were performed to find the association between dependent and independent variables using SPSS version 22.
Results:
Of 96 subjects included, 52 (54.2%) subjects experienced dyslipidemia. The prevalence of dyslipidemia among those with second-line (containing protease inhibitors) and first-line (containing non-nucleoside reverse transcriptase inhibitors) ARV therapy were 80% and 39%, respectively. The use of second-line ARV therapy was associated with 6.3 times (p < 0.01; 95% CI: 2.4-17.1) increased risk of dyslipidemia compared to first-line ARV therapy.
Conclusions:
Prevalence of dyslipidemia among HIV-positive children on ARV was high with second-line ARV therapy being a risk factor.
Antiretroviral (ARV) therapy has changed the status of human immunodeficiency virus (HIV) infection from a high-mortality disease into a chronic one. One of the consequences of long-term use of ARV medications is dyslipidemia, which may progress to cardiovascular disease in the future. The aim of the study was to measure the rate of dyslipidemia among HIV-infected children receiving ARV therapy and related risk factors.
Material and methods:
A cross-sectional study was conducted at pediatric outpatient clinic, Cipto Mangunkusumo Hospital, Jakarta, Indonesia, from January to July 2019. Lipid profile was examined on 96 eligible subjects and data regarding nutritional status, clinical stage at diagnosis, latest immunosuppression status, latest viral load (VL) value, and latest ARV combination used were obtained from medical records. Bivariate and multivariate analysis were performed to find the association between dependent and independent variables using SPSS version 22.
Results:
Of 96 subjects included, 52 (54.2%) subjects experienced dyslipidemia. The prevalence of dyslipidemia among those with second-line (containing protease inhibitors) and first-line (containing non-nucleoside reverse transcriptase inhibitors) ARV therapy were 80% and 39%, respectively. The use of second-line ARV therapy was associated with 6.3 times (p < 0.01; 95% CI: 2.4-17.1) increased risk of dyslipidemia compared to first-line ARV therapy.
Conclusions:
Prevalence of dyslipidemia among HIV-positive children on ARV was high with second-line ARV therapy being a risk factor.
REFERENCES (16)
2.
et al. Prevalence of lipodystrophy and risk factors for dyslipidemia in HIV-infected children in Brazil. Braz J Infect Dis 2014; 18: 394-399.
3.
Lapphra K, Vanprapar N, Phongsamart W, Chearskul P, Chokephaibulkit K. Dyslipidemia and lipodystrophy in HIV-infected Thai children on highly active antiretroviral therapy (HAART). J Med Assoc Thai 2005; 88: 956-966.
4.
Lainka E, Oezbek S, Falck M, Ndagijimana J, Niehues T. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy. Pediatrics 2002; 110: e56.
5.
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and adolescents. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents; summary report. Pediatrics 2011; 128: 213-256.
6.
Sonego M, Sagrado MJ, Escobar G, Lazzerini M, Rivas E, Martin-Canavate R, et al. Dyslipidemia, diet and physical exercise in children on treatment with antiretroviral medication in El Salvador: a cross-sectional study. Pediatr Infect Dis J 2016; 35: 1111-11116.
7.
Nampijja D, Kumbakumba E, Bajunirwe F, Kiwanuka J. Dyslipidemia and its correlates among HIV infected children on HAART atending Mbarara regional referral hospital. Int Clin Pathol J 2017; 4: 1-17.
8.
Brewinski M, Megazzini K, Hance LF, Cruz MC, Pavia-Ruz N, Negra MD, et al. Dsylipidemia in a cohort HIV-infected Latin American children receiving active antiretroviral therapy. J Trop Pediatr 2011; 57: 324-332.
9.
Kementerian Kesehatan Republik Indonesia. Pedoman penerapan terapi HIV pada anak (2014). Available at: http://www.idai.or.id/professi... (Accessed: 08.08.2019).
10.
Flint OP, Noor MA, Hruz PW. The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications. Toxicol Pathol 2009; 37: 65-77.
11.
Mandal A. Dyslipidemia in HIV-infected children receiving highly active antiretroviral therapy. Indian J Pediatr 2016; 83: 226-231.
12.
Tadewos A, Addis Z, Ambachew H, Banerjee S. Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study. AIDS Res Ther 2012; 9: 1-8.
14.
ti MR. Profil lipodistrofi dan dislipidemia pada pasien prepubertas dengan HIV yang mendapat terapi ARV di Rumah Sakit Cipto Mangunkusumo. Sari Ped 2016; 18: 55-62.
15.
Wilson DP, McNeal C, Blackett P. Pediatric dyslipidemia: recommendations for clinical management. South Med J 2015; 108: 7-14.
16.
Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emitricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-260.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
